RT @drdavidliew: Each line is a different country's JAK inhibitor for RA registry, looking at drug stopped for adverse e
Tweet Content
Each line is a different country's JAK inhibitor for RA registry, looking at drug stopped for adverse events.
Why all the variation?
(Until we sort that out, we'll struggle to assess JAKi post-marketing safety...)
@k_lauper's JAK-pot study POS0093 #EULAR2021 @RheumNow https://t.co/YykoG7LlEw
Show on Archive Page
On
Display in Search Results
On
PDQ
Off